

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 10/16/18

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage	
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease (2)	Discontinued		
		Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2)	Phase III		
		Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2)	Approved 10/18		
		VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2)	Phase III		
Cardiovascular and Metabolism	INVOKANA® (canagliflozin)	Infrainguinal revascular (2)	Phase III		
		Pediatric VTE (2)	Phase III		
		Diabetic Nephropathy (2)	Phase III	Phase III	
Cardiovascular and Metabolism	aprocitentan	Reduce the composite risk of CV death, MI or stroke in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R) (2)	Filed 9/17	Approved 9/18	
		Resistant Hypertension (2)	Phase III	Phase III	
Immunology	TREMIFYA® (guselkumab)	Psoriatic arthritis	Phase III	Phase III	
		Psoriasis Patient-Controlled Injector	Filed 3/18	Approved 7/18	
	SIMPONI ARIA® (golimumab) STELARA® (ustekinumab)	Crohn's Disease	Phase III	Phase III	
		Juvenile Idiopathic Arthritis (JIA)	Phase III	Phase III	
Immunology	aprocitentan	Pediatric Psoriasis (6-12 year olds)	Phase III	Phase III	
		Ulcerative Colitis	Phase III	Phase III	
		Lupus	Phase III	Phase III	
		Resistant Hypertension (2)	Phase III	Phase III	
Infectious Diseases and Vaccines	SYMITUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Approved 7/18	Approved 9/17	
		Rilpivirine Long Acting nanosuspension for injection	Phase III	Phase III	
		pimodivir (JNJ-3872)	Phase III	Phase III	
Neuroscience	esketamine	Treatment-resistant depression	Filed 9/18	Filed 10/18	
		Major depressive disorder with imminent risk for suicide	Phase III	Phase III	
	ponesimod	Relapsing multiple sclerosis	Phase III	Phase III	
	paliperidone palmitate 6 month long-acting injectable	Treatment of Schizophrenia	Phase III	Phase III	
Oncology	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006) (2)	Phase III	Phase III	
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Approved 5/18	Approved 8/18	
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III	
		Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III	
		Relapsed Refractory multiple myeloma w/carfilzomib/dex (Amgen sponsored) (2)	Phase III	Phase III	
		Amyloidosis (AMY 3001) (2)	Phase III	Phase III	
		Subcutaneous (SC) formulation (MMY3012) (2)	Phase III	Phase III	
		Smoldering multiple myeloma (SMM3001) (2)	Phase III	Phase III	
		IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
			Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
	Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)		Discontinued	Discontinued	
	Previously Treated Adults with Waldenstrom's Macroglobulinemia with Rituximab (PCYC-1127) (2)		Approved 8/18	Phase III	
	Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)		Phase III	Phase III	
	Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)		Filed 8/18	Phase III	
	Frontline Chronic Lymphocytic Leukemia IV fixed duration (CLL-3011) (2)		Phase III	Phase III	
	Frontline Chronic graft-versus-host-disease (cGVHD) (2)		Phase III	Phase III	
	Relapsed/refractory patients with Mantle Cell Lymphoma (MCL) in combination with venetoclax (2)		Phase III	Phase III	
	ERLEADA™ (apalutamide)		Prostate cancer non-metastatic castration-resistant	Approved 02/18	Filed 02/18
		Metastatic hormone sensitive prostate cancer	Phase III	Phase III	
		Localized prostate cancer	Phase III	Phase III	
Prostate Cancer metastatic castration resistant chemotherapy naïve		Phase III	Phase III		
Pulmonary Hypertension	erdafitinib (FGFR1 kinase inhibitor)	Urothelial cancer (2)	Filed 9/18	Phase IIb	
		Fontan-palliated in adolescent (>12 years old) and adult patients	Phase III	Phase III	
Pulmonary Hypertension	OPSUMIT®	Pediatric pulmonary arterial hypertension	Phase III	Phase III	
		Chronic thromboembolic pulmonary hypertension	Filed 4/18	Filed 8/18	
Pulmonary Hypertension	UPTRAVI® IV	Pulmonary arterial hypertension	Phase III	Phase III	

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; SYMTUZA developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with Viiv Healthcare; aprocitentan developed in collaboration with Idorsia; XARELTO co-developed with Bayer HealthCare; paliperidone palmitate includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.;

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of October 16, 2018

NMEs APPROVED 2017/2018	NMEs IN REGISTRATION	NME PLANNED FILINGS 2019-2021*	
Immunology	Oncology	Oncology	Neuroscience
TREMFYA® (guselkumab) Psoriasis	ERLEADA™ (apalutamide) (EU) Non-metastatic prostate cancer	Niraparib Metastatic castration-resistant prostate cancer (mCRPC)	Ponesimod Relapsing multiple sclerosis
	Erdafitinib (FGFRI kinase inhibitor) (US) Urothelial cancer		
		BCMA CAR-T Multiple Myeloma	Infectious Diseases & Vaccines
ERLEADA™ (apalutamide) (US) Non-metastatic prostate cancer	Neuroscience	Erdafitinib (FGFRI kinase inhibitor) (EU) Urothelial cancer	Pimodivir Influenza A
	Esketamine Treatment resistant depression		

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.; CAR-T licensed from Legend Biotech.

